CN1092658C - 5－(2－(4－(1,2－苯并异噻唑－3－基)－1－哌嗪)乙基)－6－氯－1,3－二氢－2(1h)－吲哚－2－酮（ziprasidone)的甲磺酸盐三水合物,其制备及其作为多巴胺d2拮抗物的用途 - Google Patents

5－(2－(4－(1,2－苯并异噻唑－3－基)－1－哌嗪)乙基)－6－氯－1,3－二氢－2(1h)－吲哚－2－酮（ziprasidone)的甲磺酸盐三水合物,其制备及其作为多巴胺d2拮抗物的用途 Download PDF

Info

Publication number
CN1092658C
CN1092658C CN97194243A CN97194243A CN1092658C CN 1092658 C CN1092658 C CN 1092658C CN 97194243 A CN97194243 A CN 97194243A CN 97194243 A CN97194243 A CN 97194243A CN 1092658 C CN1092658 C CN 1092658C
Authority
CN
China
Prior art keywords
ziprasidone
trihydrate
dihydro
benzisothiazol
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN97194243A
Other languages
English (en)
Chinese (zh)
Other versions
CN1216990A (zh
Inventor
弗兰克·R·布希
卡罗尔·A·罗斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN1216990A publication Critical patent/CN1216990A/zh
Application granted granted Critical
Publication of CN1092658C publication Critical patent/CN1092658C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN97194243A 1996-05-07 1997-03-26 5－(2－(4－(1,2－苯并异噻唑－3－基)－1－哌嗪)乙基)－6－氯－1,3－二氢－2(1h)－吲哚－2－酮（ziprasidone)的甲磺酸盐三水合物,其制备及其作为多巴胺d2拮抗物的用途 Expired - Lifetime CN1092658C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1653796P 1996-05-07 1996-05-07
US60/016,537 1996-05-07

Publications (2)

Publication Number Publication Date
CN1216990A CN1216990A (zh) 1999-05-19
CN1092658C true CN1092658C (zh) 2002-10-16

Family

ID=21777622

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97194243A Expired - Lifetime CN1092658C (zh) 1996-05-07 1997-03-26 5－(2－(4－(1,2－苯并异噻唑－3－基)－1－哌嗪)乙基)－6－氯－1,3－二氢－2(1h)－吲哚－2－酮（ziprasidone)的甲磺酸盐三水合物,其制备及其作为多巴胺d2拮抗物的用途

Country Status (45)

Country Link
US (1) US6110918A (enExample)
EP (1) EP0904273B1 (enExample)
JP (1) JP3102896B2 (enExample)
KR (1) KR100333214B1 (enExample)
CN (1) CN1092658C (enExample)
AP (1) AP838A (enExample)
AR (1) AR007003A1 (enExample)
AT (1) ATE236902T1 (enExample)
AU (1) AU730856C (enExample)
BG (1) BG63601B1 (enExample)
BR (1) BR9708932A (enExample)
CA (1) CA2252895C (enExample)
CO (1) CO4940465A1 (enExample)
CZ (1) CZ289216B6 (enExample)
DE (1) DE69720719T2 (enExample)
DK (1) DK0904273T3 (enExample)
DZ (1) DZ2221A1 (enExample)
EA (1) EA001180B1 (enExample)
EG (1) EG24401A (enExample)
ES (1) ES2192264T3 (enExample)
GT (1) GT199700042A (enExample)
HN (1) HN1997000040A (enExample)
HR (1) HRP970235B1 (enExample)
HU (1) HU229057B1 (enExample)
ID (1) ID17504A (enExample)
IL (1) IL126590A (enExample)
IS (1) IS2301B (enExample)
MA (1) MA26427A1 (enExample)
ME (1) ME00901B (enExample)
MY (1) MY128051A (enExample)
NO (1) NO312513B1 (enExample)
NZ (2) NZ508303A (enExample)
OA (1) OA10908A (enExample)
PL (1) PL188164B1 (enExample)
PT (1) PT904273E (enExample)
SI (1) SI0904273T1 (enExample)
SK (1) SK282674B6 (enExample)
TN (1) TNSN97073A1 (enExample)
TR (1) TR199802241T2 (enExample)
TW (1) TW427989B (enExample)
UA (1) UA47467C2 (enExample)
UY (1) UY24543A1 (enExample)
WO (1) WO1997042190A1 (enExample)
YU (1) YU49398B (enExample)
ZA (1) ZA973875B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
DE69910706T2 (de) * 1998-05-26 2004-07-08 Pfizer Products Inc., Groton Medikament zur Behandlung von Glaukoma und ischämischer Retinopathie
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
YU43702A (sh) 1999-12-23 2004-11-25 Pfizer Products Inc. Farmaceutske kompozicije koje obezbeđuju povećanje koncentracije leka
KR20030007824A (ko) * 2000-06-02 2003-01-23 화이자 프로덕츠 인크. 정신의학적 장애 및 안질환의 치료를 위한ｓ-메틸-디히드로-지프라시돈
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
US7488729B2 (en) 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
JP2007502856A (ja) * 2003-05-16 2007-02-15 ファイザー・プロダクツ・インク 精神病性障害および抑うつ性障害の治療
BRPI0410419A (pt) * 2003-05-16 2006-05-30 Pfizer Prod Inc tratamento para a ansiedade com ziprasidona
EP1626722A1 (en) * 2003-05-16 2006-02-22 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
US7678799B2 (en) * 2003-06-03 2010-03-16 Teva Pharmaceutical Industries Ltd. Crystalline ziprasidone HCl and processes for preparation thereof
KR20060115350A (ko) * 2003-09-02 2006-11-08 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
CA2543805A1 (en) * 2003-10-24 2005-05-06 Gideon Pilarsky Processes for preparation of ziprasidone
JP2007514001A (ja) * 2003-12-18 2007-05-31 テバ ファーマシューティカル インダストリーズ リミティド ジプラシドン塩基の多形形態ｂ２
EP1703898A2 (en) * 2003-12-31 2006-09-27 Alpharma, Inc. Ziprasidone formulations
ATE451367T1 (de) * 2004-02-27 2009-12-15 Ranbaxy Lab Ltd Verfahren zur herstellung von ziprasidon
US9044503B2 (en) * 2004-08-27 2015-06-02 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
EP2623095A1 (en) * 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
CA2593497A1 (en) * 2005-02-11 2006-08-17 Judith Aronhime Amorphous ziprasidone mesylate
EP1855651A4 (en) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd NANOPARTICLE COMPOSITIONS OF HETEROCYCLIC AMID DERIVATIVES
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
EP1858892A1 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd Anhydrous ziprasidone mesylate and a process for its preparation
EP1858891A2 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
AU2008254957A1 (en) * 2007-05-18 2008-11-27 Scidose Llc Ziprasidone formulations
KR100948126B1 (ko) * 2007-12-10 2010-03-18 씨제이제일제당 (주) 결정형의 지프라시돈 술폰산염, 그 제조방법, 및 그것를포함하는 약제학적 조성물
CN102234273B (zh) * 2010-04-21 2015-08-05 上海医药工业研究院 甲磺酸齐拉西酮半水合物及其制备方法
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281309A1 (en) * 1987-03-02 1988-09-07 Pfizer Inc. Piperazinyl-heterocyclic compounds
EP0584903A1 (en) * 1992-08-26 1994-03-02 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
EP0586191A1 (en) * 1992-09-01 1994-03-09 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2 Benzisothiazol-3-YL)-1-Piperazinyl)-Ethyl)-6-Chloro-1,3-Dihydro-2H-indol-2-one Hydrochloride

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281309A1 (en) * 1987-03-02 1988-09-07 Pfizer Inc. Piperazinyl-heterocyclic compounds
EP0584903A1 (en) * 1992-08-26 1994-03-02 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
EP0586191A1 (en) * 1992-09-01 1994-03-09 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2 Benzisothiazol-3-YL)-1-Piperazinyl)-Ethyl)-6-Chloro-1,3-Dihydro-2H-indol-2-one Hydrochloride

Also Published As

Publication number Publication date
EG24401A (en) 2009-04-29
PT904273E (pt) 2003-06-30
OA10908A (en) 2001-10-26
HRP970235B1 (en) 2002-08-31
NO985193L (no) 1998-11-06
PL188164B1 (pl) 2004-12-31
JP3102896B2 (ja) 2000-10-23
IS2301B (is) 2007-10-15
BG63601B1 (bg) 2002-06-28
HK1017893A1 (en) 1999-12-03
SK282674B6 (sk) 2002-11-06
NZ332219A (en) 2005-02-25
EA001180B1 (ru) 2000-10-30
YU17397A (sh) 2000-10-30
DK0904273T3 (da) 2003-07-07
CZ289216B6 (cs) 2001-12-12
DZ2221A1 (fr) 2002-12-03
SK150598A3 (en) 2000-03-13
BR9708932A (pt) 1999-08-03
IS4878A (is) 1998-10-23
CZ349498A3 (cs) 1999-09-15
HUP9902808A2 (hu) 2000-03-28
CO4940465A1 (es) 2000-07-24
PL329880A1 (en) 1999-04-12
BG102893A (en) 1999-09-30
TR199802241T2 (enExample) 1999-02-22
AP838A (en) 2000-05-03
HN1997000040A (es) 1997-06-05
KR100333214B1 (ko) 2002-06-20
IL126590A0 (en) 1999-08-17
IL126590A (en) 2001-11-25
US6110918A (en) 2000-08-29
DE69720719D1 (de) 2003-05-15
GT199700042A (es) 1998-10-02
EA199800909A1 (ru) 1999-04-29
MA26427A1 (fr) 2004-12-20
ES2192264T3 (es) 2003-10-01
HUP9902808A3 (en) 2000-04-28
ATE236902T1 (de) 2003-04-15
ME00901B (me) 2005-11-28
AU730856B2 (en) 2001-03-15
YU49398B (sh) 2005-11-28
MY128051A (en) 2007-01-31
UA47467C2 (uk) 2002-07-15
TW427989B (en) 2001-04-01
UY24543A1 (es) 2000-09-29
EP0904273A1 (en) 1999-03-31
EP0904273B1 (en) 2003-04-09
CA2252895C (en) 2002-08-20
JPH11509865A (ja) 1999-08-31
CA2252895A1 (en) 1997-11-13
TNSN97073A1 (fr) 2005-03-15
SI0904273T1 (en) 2003-08-31
NO312513B1 (no) 2002-05-21
WO1997042190A1 (en) 1997-11-13
NZ508303A (en) 2001-07-27
CN1216990A (zh) 1999-05-19
DE69720719T2 (de) 2003-11-06
ID17504A (id) 1998-01-08
HU229057B1 (en) 2013-07-29
HRP970235A2 (en) 1998-06-30
ZA973875B (en) 1998-11-06
AR007003A1 (es) 1999-10-13
KR20000010822A (ko) 2000-02-25
AP9700978A0 (en) 1997-07-31
AU1936897A (en) 1997-11-26
AU730856C (en) 2001-11-15
NO985193D0 (no) 1998-11-06

Similar Documents

Publication Publication Date Title
CN1216990A (zh) 5－(2－(4－(1,2－苯并异噻唑－3－基)－1－哌嗪)乙基)－6－氯－1,3－二氢－2(1h)－吲哚－2－酮(ziprasidone)的甲磺酸盐三水合物,其制备及其作为多巴胺d2拮抗剂的用途
CN1091769C (zh) 5-(2-(4-(1,2-苯并异噻唑-3-基)-1-哌嗪基)乙基)-6-氯-1,3-二氢-2(1h)-吲哚-2-酮(=ziprasidone)的甲磺酸盐二水合物,它的制备及其作为多巴胺d2拮抗剂的用途
JP7356496B2 (ja) Ｌｔａ４ｈ阻害剤の結晶形態
HK1017893B (en) Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one(=ziprasidone), its preparation and its use as dopamine d2 antagonist
HK1017892B (en) Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one(=ziprasidone), its preparation and its use as dopamine d2 antagonist
NZ508304A (en) Mesylate dihydrate salt of 5-(2-(4-(1,2 benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one ( ziprasidone) useful as dopamine D2 antagonist
MXPA98009242A (en) Salt mesylate trihydrate 5 - (- 2- (4- (1,2-benzoisotiazol-3-il) -1-piperazinil) ethyl) -6-chlorine-1,3-dihydro-2h-indol-2-

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20021016